EQT Foundation has invested in ClexBio, a Swiss and US-based biotechnology company with roots in Norway, specializing in the development of next-generation tissue therapies. The company leverages a differentiated scientific and technological approach to produce complex tissue structures that closely mimic human biology, opening new possibilities for regenerative medicine. This investment from EQT Foundation, along with other investors including GG1978, will help ClexBio accelerate its development of tissue therapies and position itself as a leader in this emerging field.

ClexBio is tackling a critical challenge in healthcare: the creation of bioengineered tissue for therapeutic use. Existing treatment options for many chronic diseases are not only limited, but also place a significant strain on healthcare systems. This highlights the urgent need for alternative solutions, such as tissue therapeutics, which hold strong potential for a catalytic impact across various diseases and areas of unmet medical need. Among these areas of unmet medical need is liver disease, with the only viable option for liver failure being a transplant, which is not widely available to all due to donor shortages, patient risk profile, and cost. Current cell and tissue therapies often fall short in long-term functionality and therapeutic performance, limiting their application in clinical treatments.

ClexBio’s multicomponent approach is designed to overcome these barriers by combining three different cell types that enhance performance and longevity. ClexBio is starting with a hepatocyte-based liver tissue product to restore function in end-stage liver patients. Their work holds great promise for treating a wide range of chronic diseases, aiming to scale into a multi-indication tissue therapy platform and transforming the way we approach therapeutic treatments.

The EQT Deal Team, consisting of Stefan Niedermaier, Maximilian Moser, and Anjum Rangwala is well-positioned to support ClexBio, particularly with connections to EQT’s Life Sciences portfolio and to industrial advisors in the pharmaceutical and therapeutics sectors.


Contact
Email: press@eqtfoundation.com
Phone: +46 73 465 5001

About EQT Foundation

EQT Foundation is the philanthropic arm and long-term shareholder of the global investment organization EQT, acting as a guardian of EQT’s purpose and values. The Foundation supports scientists and entrepreneurs bringing breakthrough solutions from lab to market, combining EQT’s expertise with catalytic investments and grants. With a focus on supporting scientific progress in underfunded areas of climate and health, the Foundation provides a learning platform for EQT employees to engage in philanthropy and work collaboratively across the globe to make a positive impact. For more information, please visit eqtfoundation.com and follow us on LinkedIn.

About ClexBio
ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough platform for scalable, high-throughput generation of therapeutic tissues. They represent the next generation of cell therapy, leveraging fully functional bioengineered tissues to elevate the restorative ability of cells and produce a new class of curative treatments for some of the world’s most challenging medical conditions. For more information, please visit https://www.clexbio.com/.